Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1538-1540

  Nishizawa, Toshihiro ^a   Suzuki, Hidekazu ^a,b   Kurabayashi, Kumiko ^a   Masaoka, Tatsuhiro ^a   Muraoka, Hiroe ^c   Mori, Mikiji ^a   Iwasaki, Eisuke ^a   Kobayashi, Intetsu ^c   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c LSI MEDIENCE CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; CAMPYLOBACTER; CLINICAL ARTICLE; ERADICATION THERAPY; FEMALE; GYRA GENE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION;

EID: 33645768501     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1538-1540.2006     Document Type: Article

References (16)

1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
2. Boyanova, L., A. Mentis, M. Gubina, E. Rozynek, G. Gosciniak, S. Kalenic, V. Goral, L. Kupcinskas, B. Kantarceken, A. Aydin, A. Archimandritis, D. Dzierzanowska, A. Vcev, K. Ivanova, M. Marina, I. Mitov, P. Petrov, A. Ozden, and M. Popova. 2002. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin. Microbiol. Infect. 8:388-396.
3. Fujimura, S., S. Kato, K. Iinuma, and A. Watanabe. 2004. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J. Med. Microbiol. 53:1019-1022.
4. Heep, M., M. Kist, S. Strobel, D. Beck, and N. Lehn. 2000. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur. J. Clin. Microbiol. Infect. Dis. 19:538-541.
5. Kutschke, A., and B. L. M. de Jonge. 2005. Compound efflux in Helicobacter pylori. Antimicrob. Agents Chemother. 49:3009-3010.
6. Luo, N., O. Sahin, J. Lin, L. O. Michel, and Q. Zhang. 2003. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob. Agents Chemother. 47:390-394.
7. Masaoka, T., H. Suzuki, K. Kurabayashi, A. G. Kamija, and H. Ishii. 2004. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther. 20(Suppl. 1):68-73.
8. Moore, R. A., B. Beckthold, S. Wong, A. Kureishi, and L. E. Bryan. 1995. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39:107-111.
9. National Committee for Clinical Laboratory Standards. 2004. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing; 14th informational supplement (aerobic dilution). M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Oram, M., and L. M. Fisher. 1991. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 35:387-389.
12. Perri, F., V. Festa, A. Merla, F. Barberani, A. Pilotto, and A. Andriulli. 2003. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment. Pharmacol. Ther. 18:815-820.
13. Pilotto, A., M. Franceschi, M. Rassu, G. Leandro, L. Bozzola, F. Furlan, and F. Di Mario. 2000. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig. Liver Dis. 32:667-672.
14. Sharara, A. I., H. F. Chaar, E. Racoubian, O. Moukhachen, K. A. Barada, F. H. Mourad, and G. F. Araj. 2004. Efficacy of two rabeprazole/gatifloxacin- based triple therapies for Helicobacter pylori infection. Helicobacter 9:255-261.
15. Tankovic, J., C. Lascols, Q. Sculo, J.-C. Petit, and C.-J. Soussy. 2003. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47:3942-3944.
16. Toro, C., J. Garcia-Samaniego, J. Carbo, A. Iniguez, T. Alarcon, M. Lopez-Brea, and M. Baquero. 2001. [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]. Rev. Esp. Quimioter. 14:172-176.